🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Bevacizumab combined with Oxaliplatin and TAS-102

    The First People's Hospital of Lianyungang

    Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  2. Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  3. BinD19

    The First People's Hospital of Lianyungang

    Relapsed B-cell Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  4. Binimetinib

    United Therapeutics Europe Ltd

    Locally Advanced Pancreatic Carcinoma

    phase 2 small molecule terminated

    1 trial

  5. Binimetinib

    United Therapeutics Europe Ltd

    Metastatic Colorectal Carcinoma

    phase 2 small molecule completed

    1 trial

  6. Bispecific antibody-based combined with CAR-T cell therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  7. Bisphosphocin Nu-3

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infections

    phase 2 small molecule completed

    1 trial

  8. Bivamelagon

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule active

    1 trial

  9. Blautix

    4D Molecular Therapeutics

    Irritable Bowel Syndrome

    phase 2 mab completed

    1 trial

  10. Bleomycin medac, 15 000 RÜ süstelahuse pulber

    The George Institute

    VASCULAR MALFORMATION

    phase 2 small molecule active

    1 trial

  11. Blinatumomab

    The First People's Hospital of Lianyungang

    B-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  12. Blinatumomab plus Reduced-dose Chemotherapy

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  13. BoNT A

    United Therapeutics Europe Ltd

    Traumatic Brain Injury

    phase 2 small molecule active

    1 trial

  14. Bomedemstat

    The University of Hong Kong

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  15. Braftovi 75 mg hard capsules, Erbitux 5 mg/mL solution for infusion

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER

    phase 2 small molecule active

    1 trial

  16. Braftovi 75 mg hard capsules, Mektovi 15 mg film-coated tablets

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. Brentuximab Vedotin

    United Therapeutics Europe Ltd

    Ann Arbor Stage IB Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  18. Briquilimab

    Jasper Therapeutics

    Chronic Urticaria

    phase 2 small molecule active

    1 trial

  19. Briquilimab

    Jasper Therapeutics

    Chronic Inducible Urticaria

    phase 2 small molecule terminated

    1 trial

  20. Briquilimab

    Jasper Therapeutics

    Urticaria Chronic

    phase 2 small molecule active

    1 trial

  21. Briquilimab

    Jasper Therapeutics

    Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  22. Bupivacaine HCI without epinephrine

    Heron Therapeutics

    Post-Operative Pain

    phase 2 small molecule completed

    1 trial

  23. Buprenorphine and Outpatient Parenteral Antibiotic Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Use

    phase 2 small molecule completed

    1 trial

  24. Busulfan 6 mg/ml concentrate for solution for infusion, THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion, Fludarabine Accord Healthcare 25 mg/ml solution à diluer pour solution injectable /pour perfusion

    The George Institute

    High-risk myeloïd malignancies

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources